Common Side Effects of Cibinqo
Cibinqo (abrocitinib), a JAK inhibitor for moderate-to-severe atopic dermatitis, causes upper respiratory tract infections in about 13% of patients, more often than placebo (9%). Headache occurs in 9%, acne in 6%, and herpes viral infections (like cold sores) in 4-5%. These are typically mild to moderate.[1]
Serious Side Effects and Warnings
Serious risks include major adverse cardiovascular events (MACE) like heart attack or stroke, especially in those 50+ with cardiovascular risk factors—seen in 0.4% vs. 0.1% on placebo. Blood clots (thrombosis), including deep vein thrombosis and pulmonary embolism, occur at higher rates (0.3% vs. 0.1%). Malignancies rise slightly (0.6% vs. 0.2%), and deaths from all causes are 0.4% vs. 0.1%. Retinal detachment and vasculitis are rare but reported.[1][2]
Infections and Immune Risks
As a JAK inhibitor, Cibinqo increases serious infection risk, including tuberculosis, herpes zoster (shingles, 3-4% vs. 1%), and opportunistic infections like Pneumocystis. Avoid starting in active infections; monitor for tuberculosis before and during use.[1]
Blood and Liver Issues
Lab abnormalities include elevated creatine kinase (muscle enzyme, 1-2%), low neutrophils (1%), low lymphocytes (up to 20%), and anemia. Liver enzyme increases happen in 3-7%. Dose adjustments or discontinuation may be needed.[1]
How Long Do Side Effects Last?
Most common effects like infections or headache resolve within weeks, but monitoring is lifelong due to cumulative risks like cancer or clots. Discontinuation reduces risks, but data on reversibility is limited.[2]
Who’s at Higher Risk?
Patients over 65, smokers, or those with heart disease, clots, cancer history, or diabetes face elevated MACE, thrombosis, and malignancy risks. Not recommended in these groups unless benefits outweigh risks.[1]
Differences from Other JAK Inhibitors
Compared to Rinvoq (upadacitinib), Cibinqo has similar infection rates but lower rates of serious infections in trials. Olumiant (baricitinib) shows comparable cardiovascular warnings across the class. All carry boxed warnings for infections, MACE, clots, cancer, and death.[2]
[1] Cibinqo Prescribing Information, Pfizer, https://labeling.pfizer.com/ShowLabeling.aspx?id=16296
[2] FDA Drug Safety Communication on JAK Inhibitors, https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-serious-heart-related-risks-cancer-and-blood-clots-janus-kinase-jak